Sutro Biopharma (STRO) Income towards Parent Company (2017 - 2025)
Sutro Biopharma recorded quarterly Income towards Parent Company of -$46.8 million in Q4 2025, up 17.77% quarter-over-quarter from -$56.9 million in Q3 2025, and down 130.64% year-over-year from $152.6 million in Q4 2024.
Sutro Biopharma's Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$46.8 million for Q4 2025.
- In Q4 2025, Income towards Parent Company fell 130.64% year-over-year to -$46.8 million; the TTM figure through Dec 2025 stood at -$180.4 million (down 7418.17% YoY), while the FY2025 annual figure was -$191.1 million, down 7861.62% from the prior year.
- Income towards Parent Company came in at -$46.8 million for Q4 2025 at Sutro Biopharma, up from -$56.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $152.6 million in Q4 2024 to a low of -$65.3 million in Q1 2025.
- A 5-year average of -$25.2 million and a median of -$38.3 million in 2021 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 322.82% in 2022 and jumped 391.29% in 2024, its largest moves.
- Sutro Biopharma's Income towards Parent Company stood at -$38.1 million in 2021, then advanced by 9.26% to -$34.6 million in 2022, then soared by 189.8% to $31.1 million in 2023, then surged by 391.29% to $152.6 million in 2024, then slumped by 130.64% to -$46.8 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$46.8 million, -$56.9 million, and -$11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46.76 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -11.50 Mn |
| Mar 31, 2025 | -65.33 Mn |
| Dec 31, 2024 | 152.62 Mn |
| Sep 30, 2024 | -48.79 Mn |
| Jun 30, 2024 | -48.02 Mn |
| Mar 31, 2024 | -58.21 Mn |
| Dec 31, 2023 | 31.07 Mn |
| Sep 30, 2023 | -49.28 Mn |
| Jun 30, 2023 | -38.52 Mn |
| Mar 31, 2023 | -50.05 Mn |
| Dec 31, 2022 | -34.59 Mn |
| Sep 30, 2022 | -19.49 Mn |
| Jun 30, 2022 | -26.01 Mn |
| Mar 31, 2022 | -39.11 Mn |
| Dec 31, 2021 | -38.13 Mn |
| Sep 30, 2021 | -30.90 Mn |
| Jun 30, 2021 | -6.15 Mn |
| Mar 31, 2021 | -19.67 Mn |
| Dec 31, 2020 | -27.89 Mn |
| Sep 30, 2020 | -12.64 Mn |
| Jun 30, 2020 | -18.99 Mn |
| Mar 31, 2020 | -19.60 Mn |
| Dec 31, 2019 | -14.79 Mn |
| Sep 30, 2019 | -12.91 Mn |
| Jun 30, 2019 | -13.79 Mn |
| Mar 31, 2019 | -16.59 Mn |
| Dec 31, 2018 | -1.49 Mn |
| Sep 30, 2018 | -10.24 Mn |
| Jun 30, 2018 | -11.54 Mn |
| Mar 31, 2018 | -12.05 Mn |
| Dec 31, 2017 | -15.46 Mn |
| Sep 30, 2017 | -1.24 Mn |